Molecule Details
| InChIKey | OSFCMRGOZNQUSW-UHFFFAOYSA-N |
|---|---|
| Canonical SMILES | COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cccc4c(=O)c5cccc(OC)c5[nH]c34)cc1)CC2 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 6.65 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB04881 |
|---|---|
| Drug Name | Elacridar |
| CAS Number | 143664-11-3 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. Development is as... |
Categories: BCRP/ABCG2 Inhibitors Benzocycloheptenes Drug Resistance, Multiple Heterocyclic Compounds, Fused-Ring Isoquinolines P-glycoprotein inhibitors
Cross-references: BindingDB: 50206310 CHEMBL396298 ChemSpider: 106620 D03968 PDB: R0Z PubChem:119373 PubChem:175426884 ZINC: ZINC000003915436
Target Activities (2)
DrugBank Target Actions (4)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P08183 | ABCB1 | ATP-dependent translocase ABCB1 | inhibitor | targets |
| P21439 | P21439 | Phosphatidylcholine translocator ABCB4 | modulator | targets |
| P08183 | ABCB1 | ATP-dependent translocase ABCB1 | inhibitor | transporters |
| Q9UNQ0 | ABCG2 | Broad substrate specificity ATP-binding cassette transporter ABCG2 | inhibitor | transporters |